Secondary Logo

Journal Logo

September 2021 - Volume 46 - Issue 9
pp: 9-56

Editor's Memo

Clinical Case Report

UpToDate: What's New

Dermatology Dilemmas

Notalgia paresthetica: An underdiagnosed condition in primary care

Haney, Beth

The Nurse Practitioner. 46(9):40-46, September 2021.

Notalgia paresthetica is a perplexing diagnosis in the primary care setting. Chronic itching, paresthesia, or pain causes discomfort in patients who suffer with notalgia paresthetica and it is thought to be a common but underdiagnosed condition. Recognition of this dermatologic condition can lead to reassurance and relief for affected patients.

Medication Update


Antihypertensive therapy in patients with moderate to severe aortic stenosis

El Hussein, Mohamed Toufic; Harvey, Giuliana; Bueckert, Alexi

The Nurse Practitioner. 46(9):14-22, September 2021.

Patients with aortic stenosis are at risk for developing hypertension. This article provides an overview of antihypertensives used in patients with aortic stenosis, focusing on renin-angiotensin system inhibitors, beta-blockers, diuretics, and vasodilators.


Underscoring the importance of advance care planning

DiBello, Karol

The Nurse Practitioner. 46(9):24-29, September 2021.

Advance care planning is an essential part of routine medical care. It is a billable, iterative process that can result in the completion of advance directives and medical orders, offering NPs the opportunity to assure goal-concordant care for their patients at the end of life.


A-SMART Lifestyle Behaviors Model for health, wellbeing, and immune system enhancement

Downes, Loureen; St. Hill, Halcyon; Mays, Traci

The Nurse Practitioner. 46(9):31-39, September 2021.

We present evidence-based lifestyle behavior interventions that enhance immunity and wellbeing, with practical applications using the A-SMART Lifestyle Behaviors Model.


Cystic fibrosis: A changing landscape

Wendekier, Camille; Wendekier-Raybuck, Katheryn

The Nurse Practitioner. 46(9):48-55, September 2021.

Cystic fibrosis is an autosomal recessive genetic disorder that causes a lifetime of debilitating and potentially fatal complications affecting the lungs and other organ systems. Over 1,700 gene mutations that cause this rare disorder have been identified. This article describes the current treatment landscape for adults with CF, including the 2019 FDA approval of a breakthrough triple-drug combination therapy that may significantly improve the quality of life for an estimated 90% of patients with CF.